Gene editing trial for chronic granulomatous disease
Part of Blood & lymphatic, Genetic & congenital, Immune system & allergy clinical trials.
This trial tests a new gene editing treatment called PM359 for people with a specific type of chronic granulomatous disease (CGD) caused by a delGT mutation in the NCF1 gene. The goal is to see if it's safe and helps fight infections and inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have CGD caused by the delGT mutation in the NCF1 gene (p47phox deficiency).
- You have been treated at a specialized CGD center for at least 2 years.
- You are willing to take part in this study and a long-term follow-up for up to 15 years total.
- You have had at least one serious CGD infection, or have a current serious infection that is not responding to treatment, OR you have an active CGD-related autoimmune or inflammatory condition that needs treatment.
- If you are under 16, you cannot have a fully matched related stem cell donor available.
- You cannot have active blood infections or other conditions that would make stem cell transplant unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new gene therapy for people with a rare immune disorder called chronic granulomatous disease (CGD), which causes repeated infections. The treatment uses a modified virus to deliver a healthy gene to your blood stem cells, potentially helping your immune system fight off bacteria and fungi. The goal is to reduce the risk of severe infections and improve overall health.
This trial tests a new gene therapy for chronic granulomatous disease (CGD), a condition that makes people prone to severe infections. The therapy uses a modified virus to fix the faulty gene in your blood cells, which may help your immune system fight infections better.
This study tests a stem cell transplant using a special conditioning regimen to treat chronic granulomatous disease (CGD), a condition that causes repeated infections and inflammation. The transplant aims to replace faulty immune cells with healthy ones from a donor, potentially reducing infections and improving quality of life.
This early-phase trial tests whether an mRNA-based treatment can correct a key immune problem in people with chronic granulomatous disease (CGD). It may help your immune cells work better against infections, but this is mainly to check safety and early signs of benefit.
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
This trial tests a new gene-editing treatment for men with a specific genetic mutation that causes X-linked chronic granulomatous disease (CGD). The goal is to fix the faulty gene in your own blood stem cells to help your immune system fight infections better.
Hear when a new Chronic Granulomatous Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.